21 March 2017Pharma

Video interview: Taylor Wessing on SPCs at the CJEU

There have been two significant references on issues that have been "left hanging" by the Court of Justice of the European Union (CJEU) in the last spate of decisions, says Paul England, senior associate at Taylor Wessing, in a video interview with LSIPR.  England discusses the two important references to the CJEU with regard to supplementary protection certificates.  Here he covers the Teva v Gilead Sciences and Abraxis Bioscience references, and talks about the importance of these cases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
24 September 2026   An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.
Pharma
22 September 2026   After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.
Pharma
17 September 2026   Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.